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Abstract
The physics concepts and methodology of designing a radioisotope
production facility based on a cyclotron is discussed with particular
reference to manufacturing commercially useful isotopes known as
radiopharmaceuticals.  Commercially available cyclotron systems will
be discussed and a conceptual facility will be described;  the isotope
most used in nuclear medicine, thallium 201, a heart imaging agent,
will be used as a case study isotope.  The requirements of Good
Manufacturing Practice for the isotope products and the necessary
compliance with regulatory approvals will be outlined.
1 . INTRODUCTION
Cyclotron-produced radioisotopes were first developed for medical purposes at the
University of California, Berkeley, in 1936.  For the next 30 years cyclotron construction
proliferated amongst universities and national research laboratories with increasing interest from
commercial organisations for processing the isotopes as radiochemicals.  However, in the early
1960's genuine medical applications for several isotopes were identified, e.g. fluorine-18,
rubidium-81 etc. and the first cyclotron project totally dedicated to commercial isotopes
production was established in the UK by The Radiochemical Centre (now known as Amersham
International).  For the period 1965-78 several 'first generation' cyclotrons were constructed,
such as the early Cyclotron Corporation cyclotrons.  These were essentially research cyclotrons
simplified for industrial operations.  However, from approximately 1975 onwards well-
engineered, user-friendly or 'second generation' compact machines became available, e.g.
Scanditronix MC-40 series.  A significant technical leap was taken in 1988 when IBA in
Belgium developed a high intensity, low cost cyclotron with negative ion acceleration, high
efficiency extraction and with fully automated controls.  Concurrently with the development of
these 30 to 40 MeV cyclotron models, several medically useful cyclotron isotopes were also
being licensed, e.g. gallium-67, iodine-123 etc.;  by 1980 thallium-201 was available for
cardiac imaging and has now become the most important commercial cyclotron isotope  In
addition to the growth in the medical applications of cyclotron isotopes, legislation for
pharmaceuticals was being extended to include these cyclotron produced materials, i.e. they
became radiopharmaceuticals.  
Therefore, a present-day production facility will consist of a cyclotron, several beam lines
and mechanical transport systems and a target arrangement which is custom built to be handled
in the different chemical extraction processes for producing pure radiochemicals and then in the
pharmaceutical production systems for producing sterile, injectable materials which comply
with the pharmaceutical or drug licensing requirements of many countries.  The underlying
physics and chemistry of producing cyclotron radiopharmaceuticals will be discussed and a
design of a conceptual facility will be developed within the text.
2 . ISOTOPES AVAILABLE FROM CYCLOTRONS
Present-day radiopharmaceutical grade cyclotron isotopes are used for imaging and
diagnosis at nuclear medicine centres worldwide.  A typical three-dimensional tomographic
heart image section is shown in Fig. 1 using thallium-201.  Some 2-3 million patient
procedures are undertaken each year using materials produced from cyclotrons.  The most
common cyclotron produced isotopes are given below in Table 1.
Fig. 1  Typical three-dimensional tomographic heart image
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Monoclonal antibody / infection imaging
etc.
Myocardial imaging (heart)
Tumour location (soft tissue)
Calibration devices for cameras
Although even shorter-lived isotopes are also produced by a cyclotron, for the purpose of
this discussion these very short lived isotope (PET or Positron Emission Tomography isotopes,
Table 2) will not be discussed since their commercial usage and distribution have not yet been
realised.  In general most of the commercially useful radiopharmaceutical isotopes have half
lives of the order of 1-7 days and their production reactions are given in Table 3.
Table 2
Common PET isotopes







Tl-203 (p,3n) Pb-201 →Tl-201
Zn-68 (p,2n) Ga-67
Cd-112 (p,2n) In-111
Xe-124 (p,2n) Cs-123 →Xe-123 →I-123
Kr-82 (p,2n) Rb-81 →Kr-81m
Ni-58 (p,2n) Co-57
The most commonly used commercial cyclotron isotope is thallium-201 which as a
potassium analogue, is readily absorbed within the muscle tissue of the heart, i.e.. the
myocardium.  Thallium imaging is used to demonstrate blood flow within the heart muscle by
imaging a patient at rest and under stress;  ischaemic tissue and infarctions can be identified
using 3D tomographic techniques.  Thallium-201 is also one of the most complicated cyclotron
isotopes to manufacture and the specification of a licensed thallium radiopharmaceutical or drug
is summarised in Table 4.
Table 4
Specification of thallous (Tl-201) chloride injection
Half life 73.1 hours
Energy of gamma rays 0.068 to 0.082 (Hg K X rays)
Radionuclidic impurity Tl-202< 1.9%
Tl-200< 1.0%
Pb-203 < 0.25%
Specific activity > 3.7 GBq. m g-1 (or 100 mCi per m gm)
Chemical form Sterile, isotonic, aqueous solution of thallous chloride
plus 0.9% (v/v) benzyl alcohol and 0.95% (w/v) sodium
chloride
Reference day Average 6 days post bombardment
Expiry day Reference day + 3
Administration:
Normal dosage
Whole body absorbed dose
Upper large intestine wall
55.5 MBq or 1.5 mCi
2.4 MBq or 0.06 rad
27.7 MBq or 0.74 rad
The features of this pharmaceutical isotope material are:
– the energy of the gamma radiation is high enough to penetrate tissue but still low enough
for efficient gamma camera detection, i.e.. around 50fi 250 keV energy range.
– radionuclidic impurities must usually be less than 1-2% since any longer half-life isotopes
contribute to increasing patient radiation dose and to blurring of images.
– half lives are approximately 3 days, which is a convenient time period for the
manufacture, delivery and administration of the material to the patient.
– the specific activity of the isotope must be high enough to produce sufficient events or
counts in the required organ using a gamma camera imaging system.
– the radiopharmaceutical must be manufactured according to the protocols of "Good
Manufacturing Practice".
– the specification and manufacturing protocols must comply with approved drug licence
conditions issued by the appropriate Government bodies.
3 . BOMBARDMENT AND ISOTOPE PRODUCTION PROCESS
For the purpose of this section the heart imaging agent thallium-201 will be used as a
'case study';  the overall production of this isotope will include the following steps:
– Preparation of a target using as a starting material the enriched isotope thallium-203,
– Bombardment by a 25-30 MeV cyclotron proton beam,
– First chemical separation process to produce the intermediate or daughter  isotope
lead-201,
– Secondary chemical separation of the radioactive isotope thallium-201,
– Pharmaceutical production of the sterile, radioactive, injectable thallous chloride.
Other important isotopes such as gallium-67, iodine-123 and indium-111 are produced by
very similar manufacturing processes.  The preferred production reaction for producing
thallium-201 is shown below;  in fact lead-201  is generated first.
decay
Thallium-203 (p,3n) Lead-201   → Thallium-201
Naturally occurring thallium consists of two main isotopes - thallium-203 (natural
abundance 29.5%) and thallium-205 (natural abundance 70.5%);  the initial raw material for
cyclotron targets is the enriched stable isotope - thallium-203.  Enriched isotopes are produced
usually by large electromagnetic separators located within Government controlled
establishments, producing mainly uranium-235 for fuel and weapons applications.  The original
'calutron devices' at Oak Ridge are now 40 years old and are based on the concept of a 180 °
magnetic spectrometer and use large dipole magnets.  Radioisotope production consumes a few
kilograms of these materials annually worldwide and the enrichment requirements for the
different isotopes are given below in Table 5.
The excitation cross sections for proton bombardment of thallium-203 are given in Fig. 2,
indicating peak energies for the reactions (p,n), (p,2n) and (p,3n) etc.  In addition, similar
production cross sections exist for protons bombarding thallium-205 indicating that even a trace
impurity level of thallium-205 within the target material thallium-203 will lead to radioactive





































Fig. 2  Excitation cross sections for Thallium 203
From the graphs in Fig. 2 it is possible to determine:
– The maximum bombardment energy for the proton beam; in this case it is determined by
the impurity radionuclide lead-200 created via the reaction (p,4n), resulting in a daughter
product Tl-200 which has a half life of 26 hours and a high energy gamma ray. This would
increase the patient dose considerably if the percentage impurity was allowed to be greater than
1%.  Consequently this fixes the maximum proton energy for thallium production at 28.5 MeV.
– The minimum bombardment energy or exit energy of the proton beam is similarly
constrained by the impurity radionuclide lead-202m created by the reaction (p,2n), the resultant
daughter product Tl-202 has a half life of 12 days and a g -emission of 1.0 MeV; the minimum
energy at the exit of the enriched Tl-203 material is similarly fixed at 22 MeV.
Table 6
Competing reactions - thallium bombardment
Reaction Initial material Radioactive products Half life
(p,4n) Tl-203 Pb-200




































(p,n) Tl-205 Pb-205 1.5x107 yrs
The energy of the proton beam is reduced during passage through the target and energy is
lost by elastic collisions, atomic excitation and ionisation.  Using the Bethe model for
relativistic velocities the expression for energy loss can be shown to be:
dE
dx
= −4.58 ×10−12 NZ
v2
ln 1.82 ×10−30 v2 / I( ) − ln 1 − β 2( ) − β 2
in units of MeV.mm-1  where:
N the number of atoms per unit volume of target material
Z the atomic number of the target material
v  proton velocity
I effective ionisation potential of target material
ß (v/c)
The stopping power in thallium is shown in Fig. 3 and the computed range of protons in
thallium as a function of energy can be derived as in Fig. 4.
Fig. 3  Stopping power in thallium Fig. 4  Computed range of protons in thallium
as a function of energy
Another parameter used in isotope production is the yield rate Ao, which represents the
macro-production cross section for a particle beam with given incident and exit energies and
represents the instantaneous production rate of the isotope (i.e. assuming no radioactive decay).
Ao takes account of target density, molecular weight of the target material, enrichment or
abundance factor of the target isotope etc. and is expressed in Curies per mA.hr.  A
comprehensive computer model and methodology has been developed by Forrest for any
production isotope and allows for energy loss and the  reactions of all the isotopes involved.  It
is assumed that a thin layer of the enriched isotope i.e. Tl-203, is deposited on a thicker cooled
target base (usually copper) and that the target assembly can be inclined at a given angle to the
direction of the proton beam.  Table 7 shows a report print out for thallium, from which the
Table 7
Summary table of yield values (Ao) – protons on thallium
design requirements for thallium bombardment can be derived.  The model also predicts the
impurity levels for the other radionuclides and also the production level of Zn-65 (half life 265
days) produced by the reaction which creates a waste disposal problem due to its 1.12 MeV
gamma ray.
Zn-65 is produced by the reaction:
Cu-65 (p,n) Zn-65
This model assumes that the remainder of the energy is deposited within the target base; the
stopping power calculation can also be used to estimate the required thickness of this copper
base to ensure full proton absorption and no penetration into the cooling liquid which is usually
water.
For a given set of irradiation conditions the activity produced is:
At = AoIt  I  -e  l t     
        l t
where At is the activity in Curies at time t
I  is the beam current in mA
t  is the bombardment time in hours
l   is  ln(2)/T
T  is the half life of the isotope produced
Tpical Ao values is given in Table 8.
Table 8
Table of yield rates Ao
Isotope Ao (Ci mA-1hr-1) Ein (MeV) Eout (MeV)
Tl-201 21.6 28.5 22.0
Ga-67 4.3 25.5 0.0
In-111 6.3 29.0 17.0
Co-57 0.032 22.0 0.0
The design requirements for thallium-201 bombardment can then be determined and are
given below in Table 9.
Table 9
Design requirement for thallium bombardment
Maximum energy 28.0 MeV Pb-200 production limitation
Minimum energy 22.0 MeV Pb-202 production limitation
dE/dx 11.9 MeV.mm-1 Derived from 28.0 MeV incidentbeam energy and 22.0 MeV exit
energy
Effective thickness 0.566 mm Calculated from above
Angle of inclination 6 ° Mechanical design considerations
Thickness of electroplating 0.06 mm
In general, for solid targets the target materials are electroplated onto metal bases, usually
having good conduction characteristics, such as copper, silver or aluminium and proprietary
electroplating methods are often used ensuring that the starting raw materials comply with the
conditions laid down in the Drug Master File, i.e. the manufacturing protocols authorised
according to the drug licence.  Criteria for electroplating include:
– Plating to completion of the electrolyte or otherwise,
– Electrical programming of the plating current cycle,
– Mechanical agitation of the target material,
– The addition of additives or shiners to enhance electro-mechanical deposition,
– Maintaining the minimum plating thickness consistent with the bombardment
requirements.
A typical electroplating station is shown in Fig. 5.
Fig. 5  A typical electroplating station
4 . DESIGN CRITERIA FOR TARGETS
In commercial manufacturing of cyclotron isotopes, the key parameter for target design
is the beam current acceptance.  Historically, production targets have been located either inside
cyclotrons as internal, glancing-angle targets on the external orbit of the correct energy or as
external targets bombarded at the end of beam lines.  For industrial operation, the heat transfer
problem of this large energy density deposition has been addressed by either adjusting the
glancing angle in the range 4° -15°  for incidence on a static target or presenting circular
Table 10
Heating calculations for a stationary target
    BEAM    PARAMETERS   
a. 1/2 beam height(m) = 0.0094
b. 1/2 beam width(m) = 0.0009
Beam current (m A) = 150
Energy (MeV) = 2 9
Q. power of beam (W) = 4350
A. projected area of beam
on target (m2) = 0.0025
q(m). Mean heat flux
(W/m2) = 1710817
q. Peak heat flux
(W/m2) = 3934879
  TARGET   PLATING   PARAMETERS  
l3. Thermal conductivity of
plating material = 44
(W/m K)
= 44
X3. Plating thickness (m)
= 0.00010
  COPPER   BACKING   PARAMETERS  
l. Thermal conductivity
of Cu (Wm/K) = 390
x. Thickness of Cu (m)
= 0.002
d. Approximate correction
factor to allow for heat
"spread out" in copper
= 0.44
    COPPER    TO      WATER
    HEAT    TRANSFER    PARAMETERS   
Copper/water heat transfer
coefficient (W/m2K) = 60800
cp. Specific heat of water
at 20o C (J/kg K) = 4186
nb. Viscosity of water at
20o C (J/kg K) = 0.001
lb. Thermal conductivity of water
at 20o C (W/m) = 0.602
Pr. Prandtl number = 6.95
d. Depth of water channel (m)
= 0.00375
w. Width of water channel (m)
= 0.025
M. Water flow rate (kg/s)
= 1.65
m. = M/(d*w) mass flux of cooling
water (kg.m2 s) = 17600
Re. Reynolds Number
=  2md/nb = 132000
nw. Viscosity of water at the temperature
of the Cu/water surface
= 0.000548 at  50oC
   0.000283 at 100oC
   0.000183 at 150oC
   FINAL    TARGET    SURFACE
   TEMPERATURE     CALCULATION    
The peak surface temperature  
is calculated from the cooling water
temperature plus three additional
temperature rises.
1 . Water-copper (oC) = 44.8
2. Copper (oC) = 16.5
3. Plated target layer (oC)
=   6.7  
Total temperature rise (oC)
=   68.0  
Chilled cooling water temperatur
= 13.0 oC
Therefore, final peak target
surface temperature
= 81.0 oC
geometry rotating targets at high speed to ensure optimum heat transfer.  Current commercially
available cyclotrons are capable of producing external beams with good emittance control for
the current range 150 - 400 m A per beam on target.  For the purposes of this 'case study' it will
be assumed that a beam current of up to 200 m A external beam will be incident on a static target
at a glancing angle.  Typical beam emittance is of the order of 5 to 10 p  mm.mrad which
translates to available beam spot dimensions of the order of 3 - 20 mm in either dimension.
Early experimental measurement and heat conduction calculations published by Pinto (Table 10)
indicated that a temperature rise of 150 ° C would occur with an incident proton beam of
30 MeV, 200 m A on a target with no electroplated material but designed for optimum cooling.
He concluded that for production targets, temperature rises could be limited to about 150 ° C
even with electroplated target material;  this temperature is lower than the melting point of
thallium metal and would guarantee integrity of the targetry and retention of the expensive raw
material on the target surface.  This calculation was substantially improved by Forrest to allow
for the heat transfer across the interface between the electroplated layer and the base material for
several different materials.  The model also allowed for defining the optimum target inclination
angle for a given beam spot size and Table 11 indicates computed surface temperature increases
for different glancing angles based on the following assumptions:
– Optimum target mechanical design to stimulate turbulent flow with water cooling,
– Uniform electroplated material,
Table 11
Target Heating calculations for different metals and beam incident angles
dimensions of approximately 6 mm high by 20 mm wide,
– Nominal beam energy 30 MeV,
– A maximum possible proton beam current of 400 m A.
The computed surface temperatures for different incidence angles are given for typical
initial raw materials used in radiopharmaceutical production with the requirement that the
surface temperature never exceeds the melting point of the material at the reduced vapour
pressure within the target enclosure.  In general, optimisation of computed models and practical
experimentation result in the 'typical' target specification, shown in Table 12.
Table 12
Target specification
Beam current 400 m A, 30 MeV
Beam size 20 mm x 6 mm
Target inclination 6 °
Maximum power density deposition 12 kW
Maximum temperature rise of Tl-203 128 ° C
Due to the relatively high radioactivity activation levels of production targets, well
designed, remote controlled mechanical transport systems are necessary to ensure that target
integrity is maintained otherwise local contamination of radioactivity and loss of valuable
enriched isotopes could occur.  Two approaches are now used:
– Compact target transfer by pneumatically operated rabbit systems – the system designed
by TRIUMF is shown in Fig. 6.
– Railway transfer systems which remove the target assembly from the cyclotron into a
demounting station.
Fig 6  Target transfer showing rabbit (1) and target (2)
5 . CYCLOTRON SPECIFICATION
Requirements of cyclotrons for commercial isotope production are:
– Proton beams as indicated in Table 3;  the large majority of useful isotopes can be
produced by proton reactions (p,xn).
– High beam currents, since the isotope production rate is proportional to beam current.-
– Variable energy is required to accommodate all the reactions in Table 3.
– Extracted beams are preferred to allow optimisation of target design and ease of handling
– High reliability operation is essential for the production of these short-lived isotopes
which have to be delivered several times a week.
– Low radiation activation levels are essential at the cyclotron and around the target system
to allow for regular maintenance, equipment upgrades etc.
– Low operating costs are desirable for a viable, competitive commercial operation.
The present day 'third generation' compact cyclotrons have been designed specifically for
this type of commercial operation and satisfy the above requirements.  Two excellent models
are available as off-the-shelf packages, viz
IBA, Cyclone-30 designed by Yves Jongen, Louvain La Neuve, Belgium and
EBCO, TRS-30 designed by TRIUMF for EBCO Industries, Vancouver, Canada.
It is also worth mentioning Scanditronix's MC-32 NE which is a negative ion cyclotron but
does have a lower output level.  For the purposes of this paper, the Cyclone-30 is assumed.
The performance specification of the Cyclone-30 is shown in Table 13 and a drawing of the
Cyclone-30 cyclotron is shown in Fig. 7.
Table 13
IBA Cyclone-30 specification
Beam current 350-500 m A
Energy range 15-30 MeV
Extraction beam 2
Beam emittance 5-10 mm mrad
Power consumption 150 kW
Ion source External
Base vacuum 3 x 10-7 torr
Clearly the above requirements for commercial isotope production are well met by the
general system specifications of the Cyclone-30, viz
– Proton or deuteron beams can be produced efficiently.
– High extracted beam currents of 350 to 500 m A which are significantly higher than
previous 'second generation' cyclotrons, cf. 60 to 100 m A.
– The extraction foil mechanism together with a 'combination' magnet provide an adequate
range of extraction energies.
– High reliability operation is achieved by simple yet elegant magnet and RF design, well-
engineered extraction equipment, high reliability sub systems, comprehensive diagnostic
facilities and stable high beam extraction performance.
– Low radiation levels are maintained by efficient (negative ion) extraction, selection of low
activation material for construction of the cyclotron vacuum chamber etc., and low neutral
beam activation by high vacuum operation by using an external ion source.
– Low operating costs are achieved by very efficient power consumption of the main
magnet and RF systems, a high reliability operation as well as good maintainability and
access.
Fig. 7  Cyclone-30 cyclotron
The analysis in Section 4 indicated the following target demands for the extracted beam:
· stable, high current extraction
· low beam loss at extraction
· accurate reproducible extraction energy with low dispersion
· low emittance in both planes, preferably with balanced divergence.
Again, the Cyclone-30 performance meets these requirements although it is essential to ensure
that the beam size at the target location can be controlled within the "footprint" of the material on
the target thereby minimising the usage of the expensive enriched isotope material.  Figure 8
shows a typical TRANSPORT generated computer calculation of beam line optimisation for a
possible Cyclone-30 beam to give a minimum 'image' size of 20 mm x 4 mm onto an inclined
target footprint of 20 mm x 40 mm, and using the minimum length of beam line yet allowing
sufficient space for shielding between cyclotron vault and target vault.  For this particular
example the beam optics show a very large vertical beam dimension.  Beam line design for
commercial operation has to satisfy two conflicting demands:
– a small beam size at the target to minimise the usage of expensive enriched isotopes
– a short beam line length to limit the construction costs of the facility.
The final design is a compromise ensuring that beam loss in the beam lines does not lead
to excessive radiation and activation of equipment.
Fig. 8  Cyclone-30 beam optics calculated with the TRANSPORT program
6 . RADIOCHEMISTRY
In cyclotron systems, the amount of isotope generated in the targets is determined by the
sum effect of the physical processes described earlier.  Extraction of the radioisotope from the
targets is achieved by chemical or radiochemical methods.  For example, in order to achieve the
correct radiochemical formulation for thallium-201, the following processes are required:
First chemical separation:  Acid extraction of the primary product lead-201 from the initial
thallium-203 and the target base material, e.g. copper.
Second chemical separation:  Ion exchange to remove the secondary product thallium-201
from the primary product lead-201.
– Chemical recovery of the original thallium-203 from the aliquot of lead and thallium
isotopes as well as the copper impurities.
– Possible removal of the radioactive zinc-65 from the copper material in the target base
since this radionuclide constitutes a severe radioactive waste disposal issue.
The graph of Fig. 9 shows the change in radioactivity during the manufacture of Tl-201
during bombardment, the first and second chemical separations, pharmaceutical production, the
decay of Tl-201 to the reference date of the product and to the expiry date of the material.
The majority of other isotopes using solid targets, e.g. Ga-67, In-111, etc. are produced
by similar techniques although some processes may employ organic solvent extraction
chemistry.  The main exception is I-123 which is usually produced by dedicated bombardment
and processing equipment such as the gas system using Xe-124 as developed at KF Karlsruhe.
These chemical processes are performed within a facility dedicated for the production of
radiochemicals and containing heavily shielded production plant or cells with shielding
equivalent to 10 or 20 cm lead.  Each plant is usually equipped with:
· a set of manipulators,
· leaded-glass window,
· in-plant chemical equipment,
· front-panel controls for electrics and pneumatics,
· transfer ports for product flow, waste materials,
· air flow into filtered air handling unit.
The radiochemical produced has the correct chemical ingredients but not necessarily the correct
concentration, and is not sterile enough for drug purposes.
Fig. 9  Activity of thallium-201 during production, delivery and use
7 . RADIOPHARMACEUTICAL PRODUCTION
As the usage of cyclotron isotopes increased, pharmaceutical licensing requirements for
manufacturing  became more demanding.  Today, cyclotron isotopes used in nuclear medicine
are not just radiochemicals with medical applications but genuine pharmaceutical materials
incorporating a radioisotope component.  These isotope products are usually supplied in a
shielded vial container or syringe ready for injection.
The manufacture of radiopharmaceuticals include the following steps:
– container preparation and cleaning, i.e. for vials or syringes
– transfer of the radiochemical material to a pharmaceutical grade 'clean room',
– quality control of parameters such as chemical purity, radionuclidic purity, specific
activity,
– sterile dispensing of the radiochemical into its final container,
– terminal sterilisation of the final product,
– batch release of the product by the Qualified Person,
– labelling, packing, distribution, etc.
The detailed steps in this manufacturing procedure have to comply with the principles of
"Good Manufacturing Practice" (GMP).  All steps are defined in extensive documented
procedures within a Drug Master File.  This is the legal document binding the manufacturers'
operations to the conditions of the pharmaceutical licence which is awarded by Government
Regulatory bodies such as CPMP (Europe), FDA (USA).  In this way Regulatory Authorities
strive to guarantee the safety of the product and the reproducibility of the manufacturing
operation.
In order to comply with the regulatory requirements for these small volume 'parenterals',
special attention must be paid to ensure that the products are:
· pyrogen free,
· sterile,
· free of particulate material etc.
To achieve this careful control is required of:
· the manufacturing environment,
· the manufacturing processes,
· the product containers.
In addition there is also a requirement that manufacturing operations are performed in a manner
that minimises the risk of:
· cross contamination of one product by another,
· incorrect labelling of product containers etc.
A system of Quality Assurance must be in place to ensure that all processes are
documented, validated and performed repeatably in accordance with written instructions.  All
batches of materials used in processes must be tested to ensure conformance with specification;
traceability of materials through to the finished product must be maintained and batches of final
product for sale must be tested/inspected to demonstrate conformance with specification.  All
production facilities must be regularly monitored to ensure continuing performance to
specification, e.g.
· water quality in purified supplies
· air quality in clean rooms
· performance of sterilisers
· integrity of air filters
· calibration of measuring instruments
During the development phase of a new product, all processes must be systematically
validated to show that the process will produce the specified output for all inputs at the upper
and lower limits of their specification ranges.  This will include a demonstration that the product
remains stable throughout its shelf life for specified storage conditions.  All experimental and
test data must be retained and is liable to inspection by the Regulatory Authority. The finished
product must be stored and shipped in a manner that ensures that product deterioration does not
occur. Finally, the selection and training of staff is vital to the maintenance of GMP.  
8 . DESIGN OF THE FACILITY
For the purpose of this discussion, the construction of a complete radiopharmaceutical
grade facility is assumed on a green field site.
According to the principles described in Section 5, a cyclotron and associated beam lines
are selected and purchased from a specialist vendor.  Design features of the facility for
accommodating this accelerator hardware should include:
· construction of a solid base or plinth,
· construction of a complete radiological shield or vault for the cyclotron, beam lines and
target system,
· subterranean access to the cyclotron for maintenance,
· adequate headroom for access to the ion source and for lifting the upper pole of the
magnet for maintenance.
The design of a conventional radiological shield or vault should allow for:
· attenuation of the neutron flux (produced at the isotope target) to a level of
< 5 m Sv.hr-1 at the external surface of the shield
· selection of appropriate material (concrete) to ensure correct shielding efficiency
without voids and without high Z materials which result in high activation levels,
· correct design to avoid neutron (and gamma) short paths in access ducts and channels
· correct design of the movable access doors,
· fail safe interlock system for access to each vault
· adequate shielding and protection around the beamline penetrations into target vaults.
Target station design should allow for:
· remote mechanical control of the target load/unload function,
· diagnostic and monitoring of target performance parameters,
· protection against loose material contamination from the target assembler,
· installation of pneumatic controlled rabbit systems (or equivalent) with shielding to
transfer targets to their respective handling stations,
· mechanical back-up for systems 'disaster' recovery of radioactive targets,
· material specification for radiation hard materials, low-Z materials and wherever
possible, the absence of semiconductor control devices.
Support services for the accelerator/cyclotron system are:
· correctly fused, interference-free, electrical power supplies including uninterruptible
power supplies for key equipment, i.e. computers, safety systems,
· high pressure, de-ionized water supply for cooling of the targets and the cyclotron
system,
· air handling of cool, filtered air to avoid humidity and the accumulation of gaseous
radionuclides such as argon 41 with appropriate ? cycles,
· compressed air for servicing much of the mechanical (pneumatic) controls,
· mechanical engineering shop capable of machining radioactive components.
A validated waste disposal system with facility monitoring for unacceptable levels of
background radiation and contamination is necessary which includes:
· solid waste disposal and compaction of target and ancillary cyclotron components
· removal of effluent generated in the radiochemical and pharmaceutical areas
An overall facility design is shown in Fig. 10 with
· segregated areas for cyclotron operations,
· high level radioactive radiochemical processing area,
· clean room environment for radiopharmaceutical finishing operations,
· ground floor laboratories for quality control etc.,
· appropriate personnel change rooms and environmental monitoring support services
· upper storey accommodation for mechanical and electrical plant, non-radioactive
workshops, offices, etc.
· warehouse, packing and product despatch areas for the final product.
9 . CONCLUSION
The design principles of a cyclotron facility for the commercial production of
radiopharmaceuticals has been described, explaining the underlying physical principles of
design, the requirements of radiochemical production and final pharmaceutical finishing.  The
design of a "green field" facility with all the support functions at today's prices would cost
approximately £8M sterling.  However, in order to generate an adequate return on this financial
investment, sales of cyclotron isotope products of the order of £4M to £5M per year are
necessary. This can only be achieved by:
– The large manufacturers who have existing approved drug licences and large sales
organisations capable of distributing the products too numerous hospitals and medical
centres, or
– Government sponsored laboratories who usually have their capital expenditure covered
by central funds, and are allowed to operate on a cost recovery basis by producing small
volume niche products or radiochemical materials which are used by the larger
commercial manufacturers.
Although cyclotron isotopes production is essentially a commercial operation, the total
manufacturing process encompasses fundamental accelerator physics, radiochemistry and
industrial pharmaceutical technology.  This presents a very rewarding occupation to the people
working in the industry producing very valuable materials which are used by clinicians to
diagnose illness and to alleviate the suffering of many millions of people every year.
Fig. 10  Conceptual cyclotron facility
BIBLIOGRAPHY
A A Fleischer, G O Hendry, C G Smith, J L Tom and D K Wells, Design and performance of a
compact multi-particle cyclotron; Proc. Fifth Int. Cyclotron Conf., Oxford, Sept 1969
(Butterworths) p.573.
G Seaborg, Remarks at the Dedication of the Biomedical Cyclotron at UCLA, June 30 1971,
USAEC S-14-71.
J P Mamacos, P J Kinny and J S Laughlen, A Compact Cyclotron Installation for Biomedical
Uses, J.Nucl.Med.   8 (1969) 330.
Y Jongen, J L Bol, A Chevalier, M Lacroix and G Ryckewaert, Construction of the Louvain-
la-Neuve 30 MeV 500 m A H- Cyclotron, Proc. 11th Conf. on Cyclotrons & Applications,
Tokyo, 1987, p 275.
M Lagunas Solar, Cyclotron production of no carrier added medical radionuclides, IEE Trans.
on Nucl.Science, Vol. NS-30, No.2, p.1805 (1983).
Qaim, Weinrich, Ollig, Int. J. Appl. Rad. Isotopes, 30, 85 (1979).
T J Ruth, The Production of Radionuclides for the Biosciences, Proc. 13th Int. Conf.
Cyclotrons & Applications, Vancouver (World Scientific, 1992) p.206.
J Lamb, Commercial production of radioisotopes for nuclear medicine 1970-1980, IEEE Trans.
Nucl. Science (April 1981), Vol NS-28 No.2, p.1916.
K Lebourtz, S Greene and T Fairchild, J. Nucl. Med., 16, 151 (1975).
J Tracy, Isotope separation program - present and future, Nucl. Inst. & Methods in Physics
Research, 282 (1989) p.261.
G Pinto, M Straatman, D Schyler, S Curris and G O Hendry, Target systems for radioisotope
production, IEEE Trans. Nucl. Science (April 1983), Vol NS-30 No.2, p.1797.
J J Burgerjon, Z Gelbart, G O Hendry, J C Lofvendahl, L McIlwraith and G A Pinto, A high
power target system for radioisotope production, Proc. 11th Int. Conf. on Cyclotrons &
Applications, Tokyo, 1986.
T R F Forrest, A method for calculation of cyclotron product yields, Amersham International
internal report, November 1987, PTDS/R8.
T R F Forrest, Demonstration of a practical stationary target system, Amersham International
internal report, November 1987, PTDS/R10.
IBA, Ion Beam Applications SA, Chemin du Cyclotron 2, B-1348 Louvain-la-Neuve,
Belgium.
EBCO Industries Inc., 7851 Aldebridge Way, Richmond, BC, Canada V6X2A4.
Scanditronix AB, Jusbyborg, S-75229, Uppsala, Sweden.
European Communities Commission, "The Rules Governing Medicinal Products in the
European Community", Vol. IV (1989), ISBN 92-825-9572-2.
